Form 4: Tarsus Pharmaceuticals' General Counsel Sells Shares to Cover Tax Obligations

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Bryan Wahl, the General Counsel of Tarsus Pharmaceuticals, sold shares of the company's common stock on March 18, 19, and 20, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• These sales were mandated by Tarsus Pharmaceuticals' policy requiring tax obligations to be funded through 'sell to cover' transactions.
• The sales do not represent discretionary transactions by Mr. Wahl.
• On March 18, 2025, 3,341 shares were sold at $46.29 per share, leaving Mr. Wahl with 58,057 shares.
• On March 19, 2025, 3,261 shares were sold at $47.4 per share, leaving Mr. Wahl with 54,796 shares.
• On March 20, 2025, 3,084 shares were sold at $50.11 per share, leaving Mr. Wahl with 51,712 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales to cover tax obligations, a routine event.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees. These transactions are typically disclosed via Form 4 filings with the SEC.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are routinely observed across the pharmaceutical industry among executives at companies like AbbVie, Pfizer, and Johnson & Johnson.
• The scale of these transactions is generally proportional to the executive's compensation package and the number of RSUs vesting.
• The disclosure requirements and reporting practices are standardized across the industry, ensuring transparency.

Stakeholder Impact

• The stock sales may have a minor, temporary impact on the stock price due to the increased selling volume.
• The transactions do not reflect any change in the company's fundamentals or management's confidence in the business.

Key Dates

Keywords

Tarsus Pharmaceuticals, Bryan Wahl, Form 4, SEC Filing, Stock Sale, Restricted Stock Units, Tax Withholding, Sell to Cover, Insider Trading